| Followers | 13 |
| Posts | 94 |
| Boards Moderated | 0 |
| Alias Born | 12/14/2019 |
Wednesday, September 16, 2020 10:55:24 PM
Thank you for making this distinction. That sounds completely correct.
If anyone pays any attention at all to Nader’s speech it should be obvious that while he is a fluent speaker of English, his English is very imprecise. He often hesitates and struggles to find words. He sometimes uses the wrong tense and omits words like the article “the” (the proper use of which is notoriously difficult for non-native speakers to understand). He sometimes uses one word when he means another, such as mixing up Emergency Use Authorization with Emergency Use Application. If I were a teacher of English as a Second Language, I would only be able to give Nader a grade of B- for his spoken English.
IMO, this is the main reason underlying Nader’s flawed communication. Unfortunately, his imprecision often makes Nader difficult to understand clearly and this works against him.
My impression is Nader is an extremely driven and hard-working person who wants always to do the right thing.
What he is trying to accomplish with Cytodyn is an Herculean task for anyone, doubly so for him.
If anyone pays any attention at all to Nader’s speech it should be obvious that while he is a fluent speaker of English, his English is very imprecise. He often hesitates and struggles to find words. He sometimes uses the wrong tense and omits words like the article “the” (the proper use of which is notoriously difficult for non-native speakers to understand). He sometimes uses one word when he means another, such as mixing up Emergency Use Authorization with Emergency Use Application. If I were a teacher of English as a Second Language, I would only be able to give Nader a grade of B- for his spoken English.
IMO, this is the main reason underlying Nader’s flawed communication. Unfortunately, his imprecision often makes Nader difficult to understand clearly and this works against him.
My impression is Nader is an extremely driven and hard-working person who wants always to do the right thing.
What he is trying to accomplish with Cytodyn is an Herculean task for anyone, doubly so for him.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
